Candel Therapeutics (NASDAQ:CADL) Price Target Raised to $25.00 at Canaccord Genuity Group

Candel Therapeutics (NASDAQ:CADL) had its price objective boosted by Canaccord Genuity Group from $20.00 to $25.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

CADL has been the topic of a number of other research reports. Bank of America assumed coverage on Candel Therapeutics in a research note on Friday, February 7th. They set a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Candel Therapeutics in a report on Wednesday. Finally, Citigroup began coverage on shares of Candel Therapeutics in a research report on Thursday, February 20th. They issued a “buy” rating and a $25.00 price objective for the company.

Candel Therapeutics Price Performance

Shares of CADL opened at $8.47 on Wednesday. Candel Therapeutics has a 1-year low of $1.34 and a 1-year high of $14.60. The firm has a 50 day simple moving average of $8.37 and a 200-day simple moving average of $6.72. The stock has a market cap of $275.07 million, a price-to-earnings ratio of -4.90 and a beta of -1.25.

Insider Buying and Selling at Candel Therapeutics

In related news, insider Francesca Barone sold 13,673 shares of Candel Therapeutics stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $8.22, for a total value of $112,392.06. Following the completion of the sale, the insider now owns 124,207 shares in the company, valued at approximately $1,020,981.54. The trade was a 9.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Garrett Nichols sold 13,935 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $4.56, for a total value of $63,543.60. Following the sale, the insider now owns 100,547 shares in the company, valued at $458,494.32. The trade was a 12.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 75,856 shares of company stock valued at $470,044 in the last ninety days. Insiders own 41.60% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in Candel Therapeutics during the third quarter worth approximately $46,000. MetLife Investment Management LLC bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth $87,000. Atom Investors LP acquired a new stake in shares of Candel Therapeutics in the third quarter valued at $103,000. State Street Corp boosted its stake in Candel Therapeutics by 4.1% during the third quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after buying an additional 19,207 shares in the last quarter. Finally, Barclays PLC grew its holdings in Candel Therapeutics by 327.1% during the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after acquiring an additional 21,971 shares during the period. 13.93% of the stock is currently owned by institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.